Effect of telmisartan in hypertensive patients with diabetes mellitus

DOI Web Site Web Site 23 References

Bibliographic Information

Other Title
  • 2型糖尿病を有する高血圧症患者におけるテルミサルタンの血糖コントロールへの影響
  • 2ガタ トウニョウビョウ オ ユウスル コウケツアツショウ カンジャ ニ オケル テルミサルタン ノ ケットウ コントロール エノ エイキョウ

Search this article

Abstract

Objective : Telmisartan, an angiotensin II type 1 receptor blocker (ARB) with partial peroxisome proliferator-activated receptor gamma (PPAR- γ) activity, is expected to improve insulin sensitivity. We retrospectively investigated the effect of telmisartan in hypertensive patients with diabetes. Patients : This study comprised 66 hypertensive patients (39 men and 27 women, aged68.4±9.4years) with diabetes mellitus who received telmisartan (20mg-80mg/day) in our hospital. Methods : Systolic and diastolic blood pressures, HbA1c, and BMI were compared between before and 6 months after treatment with telmisartan. No patient was treated with insulin. During this period, antidiabetic drugs were not changed in any patient. Results : Telmisartan reduced systolic and diastolic blood pressures significantly (p<0.01). Although BMI was not changed, HbA1c was significantly improved (p<0.01). In 36 patients who had undergone replacement of other ARBs or ACE- I with telmisartan, either systolic or diastolic pressure decreased significantly (p<0.01).In addition, HbA1c was improved but it was not significant (p=0.06). Conclusion : Telmisartan improved not only blood pressure but also gluco-metabolic control without weight gain. This improvement of diabetic control may be related to its PPAR- γ activity.

Journal

References(23)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top